BioCentury
ARTICLE | Clinical News

Ralfinamide misses back pain endpoint

May 7, 2010 12:37 AM UTC

Newron Pharmaceuticals S.p.A. (SIX:NWRN) fell CHF11.31 (59%) to CHF7.99 on Thursday after ralfinamide missed the primary endpoint in the Phase IIb/III SERENA trial to treat neuropathic low back pain. ...